Immunocore Holdings PLC (IMCR)
32.28
+0.16
(+0.50%)
USD |
NASDAQ |
Nov 22, 16:00
32.22
-0.06
(-0.19%)
After-Hours: 20:00
Immunocore Holdings Debt to Equity Ratio: 1.161 for Sept. 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2024 | 1.161 |
| June 30, 2024 | 1.220 |
| March 31, 2024 | 1.217 |
| December 31, 2023 | 0.1302 |
| September 30, 2023 | 0.1355 |
| June 30, 2023 | 0.1374 |
| March 31, 2023 | 0.1411 |
| December 31, 2022 | 0.1411 |
| September 30, 2022 | 0.1545 |
| June 30, 2022 | 0.2523 |
| Date | Value |
|---|---|
| March 31, 2022 | 0.235 |
| December 31, 2021 | 0.217 |
| September 30, 2021 | 0.1874 |
| June 30, 2021 | 0.1651 |
| March 31, 2021 | 0.1505 |
| December 31, 2020 | 0.6623 |
| September 30, 2020 | 0.00 |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | 1.297 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
Sep 2020
1.297
Maximum
Dec 2019
0.4225
Average
0.1763
Median
Debt to Equity Ratio Benchmarks
| Adaptimmune Therapeutics PLC | 0.6234 |
| Biodexa Pharmaceuticals PLC | -- |
| Verona Pharma PLC | 0.9197 |
| NuCana PLC | -- |
| Autolus Therapeutics PLC | -- |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 1.085B |
| Total Liabilities (Quarterly) | 706.81M |
| Shareholders Equity (Quarterly) | 377.83M |
| Current Ratio | 3.778 |
| Net Debt Paydown Yield | -5.02% |